Výsledky vyhledávání - "Flavia Ejzykowicz"

Akademický článek

Challenges in conducting fractional polynomial and standard parametric network meta-analyses of immune checkpoint inhibitors for first-line advanced renal cell carcinoma

Autor: Svenja Petersohn, Bradley McGregor, Sven L Klijn, Jessica R May, Flavia Ejzykowicz, Murat Kurt, Matthew Dyer, Bill Malcolm, Sebastien Branchoux, Katharina Nickel, Saby George, Sonja Kroep

Publikováno v: Journal of Comparative Effectiveness Research (2023)

Aim: Network meta-analyses (NMAs) increasingly feature time-varying hazards to account for nonproportional hazards between different drug classes. This paper outlines an algorithm for selecting clinically plausible fractional polynomial NMA models.

Externí odkaz: https://doaj.org/article/f4ab129d0b404efd8c4b62efb4d76780

Zobrazit plný text záznamu

Conditional survival and long-term efficacy with nivolumab plus ipilimumab versus sunitinib in patients with advanced renal cell carcinoma

Publikováno v: Motzer, R J, McDermott, D F, Escudier, B, Burotto, M, Choueiri, T K, Hammers, H J, Barthélémy, P, Plimack, E R, Porta, C, George, S, Powles, T, Donskov, F, Gurney, H, Kollmannsberger, C K, Grimm, M O, Barrios, C, Tomita, Y, Castellano, D, Grünwald, V, Rini, B I, McHenry, M B, Lee, C W, McCarthy, J, Ejzykowicz, F & Tannir, N M 2022, ' Conditional survival and long-term efficacy with nivolumab plus ipilimumab versus sunitinib in patients with advanced renal cell carcinoma ', Cancer, vol. 128, no. 11, pp. 2085-2097 . https://doi.org/10.1002/cncr.34180

Background: Conditional survival estimates provide critical prognostic information for patients with advanced renal cell carcinoma (aRCC). Efficacy, safety, and conditional survival outcomes were assessed in CheckMate 214 (ClinicalTrials.gov identifi

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::25c1a5d5dc95c679e05c0ba3689162a8
https://www.ncbi.nlm.nih.gov/pubmed/35383908

Zobrazit plný text záznamu

Long-term survivorship rates among patients with previously treated advanced renal cell carcinoma receiving nivolumab: Analyses based on ≥ 7 years of follow-up from CheckMate 025 trial

Autor: Saby George, James Larkin, Kateryna Chepynoga, Daniel Sharpe, Tuli De, Matthew Dyer, Flavia Ejzykowicz, Jessica May, Murat Kurt

Publikováno v: Journal of Clinical Oncology. 41:729-729

729 Background: The phase 3 CheckMate 025 study has shown sustainable and superior long-term survival outcomes for previously treated aRCC patients receiving NIVO over everolimus. This exploratory analysis investigated the survival heterogeneity with

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::464810d54d246435959d1db7f2de686c
https://doi.org/10.1200/jco.2023.41.6_suppl.729

Zobrazit plný text záznamu

Assessing treatment preferences among patients with advanced/metastatic renal cell carcinoma in the United States: A discrete choice experiment

Autor: Moshe Chaim Ornstein, Lisa Rosenblatt, Flavia Ejzykowicz, Sarah Guttenplan, Viviana Del Tejo, Xin Yin, Kathleen M. Beusterien, deMauri S Mackie, Oliver Will, Grace Skiles, Marc DeCongelio, Steven S. Senglaub

Publikováno v: Journal of Clinical Oncology. 41:630-630

630 Background: The introduction of immunotherapies has changed the first-line treatment landscape for advanced/metastatic renal cell carcinoma (aRCC). This study examines patient preferences in this rapidly changing environment to better understand

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::643134adaedf9fc4b6085a7a76824c46
https://doi.org/10.1200/jco.2023.41.6_suppl.630

Zobrazit plný text záznamu

Patient-reported outcomes with first-line nivolumab plus cabozantinib versus sunitinib in patients with advanced renal cell carcinoma treated in CheckMate 9ER: an open-label, randomised, phase 3 trial

Autor: David Cella, Robert J Motzer, Cristina Suarez, Steven I Blum, Flavia Ejzykowicz, Melissa Hamilton, Joel F Wallace, Burcin Simsek, Joshua Zhang, Cristina Ivanescu, Andrea B Apolo, Toni K Choueiri

Publikováno v: Lancet Oncol

In the CheckMate 9ER trial, patients with advanced renal cell carcinoma who received first-line nivolumab plus cabozantinib had significantly better progression-free survival compared with those given sunitinib. In this study, we aimed to describe th

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::e0c8a0e2d55030aa9b0b247ca412a62b
https://pubmed.ncbi.nlm.nih.gov/35489343

Zobrazit plný text záznamu

Capture of common adverse events (AEs) by patient-reported outcome measures (PROMs) used in clinical trials of immuno-oncology (IO)-based combination therapies in advanced renal cell carcinoma (aRCC)

Autor: Stephen Huo, Flavia Ejzykowicz, Andrew Delgado, Karen D. Beauchamp

Publikováno v: Journal of Clinical Oncology. 40:263-263

263 Background: IO-based combination therapies have improved clinical outcomes in aRCC; several are approved for first-line use. AEs can significantly impact quality of life, and IO therapy is associated with AEs that differ from prior standard treat

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::48af4775655463236591f7b8054aa280
https://doi.org/10.1200/jco.2022.40.28_suppl.263

Zobrazit plný text záznamu

The relationship between health-related quality of life (HRQoL) and clinical outcomes in patients with advanced renal cell carcinoma (aRCC) in CheckMate (CM) 214

Autor: David Cella, Melissa Hamilton, Steven I. Blum, Cristina Ivanescu, Abi Williams, Flavia Ejzykowicz, Robert J. Motzer

Publikováno v: Journal of Clinical Oncology. 40:4502-4502

4502 Background: In CM 214, when compared to sunitinib (S), nivolumab plus ipilimumab (N+I) was associated with both clinical benefit and improved HRQoL as first-line treatment for intermediate/poor (I/P)-risk patients (pts). This analysis investigat

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::95320b49b700a9ffb844d748bf8e0469
https://doi.org/10.1200/jco.2022.40.16_suppl.4502

Zobrazit plný text záznamu

Prevalence of hypoglycemia among a sample of sulfonylurea-treated patients with Type 2 diabetes mellitus in Argentina: The real-life effectiveness and care patterns of diabetes management (RECAP-DM) study

Autor: Homero Monsanto, Claudio D. Gonzalez, Cyntia Monti, Flavia Ejzykowicz, Adolfo Pinzon

Publikováno v: Endocrinología, Diabetes y Nutrición. 65:592-602

Aim Strict blood glucose control in the treatment of diabetes can sometimes lead to hypoglycemia. The main aim of this study was to assess the prevalence of hypoglycemia among patients receiving sulfonylureas alone, or in combination with metformin,

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::59343f0c9b670d11282df52cfbac555d
https://doi.org/10.1016/j.endinu.2018.05.014

Zobrazit plný text záznamu

Vyhledávací nástroje:

Upřesnit hledání